Overview

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Status:
Terminated

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Tremelimumab